16. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis o...
TDG-associated reduced FD4 uptake was reversed by the VPAC1 antagonist PG97-269 or L-NAME, not by EGF or IGF1 receptor inhibitors.Conclusions Systemic LPS releases endogenous GLP-2, reducing LPS-related increased permeability. The therapeutic window of exogenous GLP-2 administration is at minimum...
参考文献 [1]Neuen BL, Heerspink HJL, Vart P, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional...
这项研究中,研究者检索了2024年1月31日之前PubMed、EMBASE、Cochrane图书馆和Web of Science发表的相关研究,最终分析了16项研究867例参与者(包括2型糖尿病患者、肥胖患者和2型糖尿病合并肥胖患者),16项研究包括15项随机对照试验和1项病例对照研究。 来源:Bao Y, Hu Y, Shi M, Zhao Z. SGLT2 inhibitors reduc...
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A ... S Pantelis,CJ Ferro,M Enrique,... - 《Nephrology Dialysis Transplantation》 被引量: 0发表: 2019年 SGLT-2 inhibitors and GLP-1 receptor ...
Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in...
希望进一步降低CVD和CKD结果风险的患者:弱推荐开始使用SGLT-2抑制剂,而不是GLP-1受体激动剂。 题图来源:123RF 参考资料 [1] Li S, Vandvik P O, Lytvyn L, Guyatt G H, Palmer S C, Rodriguez-Gutierrez R, et al., (2021). SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type ...
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network meta-analysis to compare the effect on cardiorenal outcomes among GLP-1 RAs, SGLT-2 inhibitors and dipeptidyl peptidase-4 (DPP-4) inhib...
[27] Luli, Alex, et al. "Barriers to Obtaining GLP-1 Receptor Agonists and SGLT2 Inhibitors in a Free Clinic Population With Type 2 Diabetes and Cardiovascular Disease." Journal of Contemporary Pharmacy Practice 70.1 (2023): 9-13.[28] Mahtta, Dhruv, et al. "Utilization rates of SGLT2...
4 Bea S, Son H, Bae JH, Cho SW, Shin JY, Cho YM. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study. Diabetes Obes Metab. 2023 Sep 21. doi: 10.1111/...